J Eur Acad Dermatol Venereol
October 2024
Aggressive CD30-positive cutaneous T-cell lymphomas (CD30CTCL) are associated with unfavorable prognosis. Anthracycline-based polychemotherapy (CHOP) and brentuximab-vedotin (BV) monotherapy are related to poor outcomes in case of extracutaneous involvement or rapidly-progressing disease. Our objective was to assess the effectiveness of BV + CHP in aggressive CD30CTCL.
View Article and Find Full Text PDF